Home / Intelligence / Webinars / Elevating Commercialization in China Part 2: The Key to Pricing and Access Optimization
Available On Demand
In Part 1 of this webinar series, The Path to Launch, we discussed various pathways and innovative programs to accelerate product launch in China. However, launching a product is only half of the battle. Ensuring optimal access to deliver the treatment to more patients is also critical for commercial success.
Join Trinity Life Sciences’ APAC experts for Part 2 as they decode recent key pricing and access dynamics in the China pharmaceutical market and explore what strategies and levers are available to elevate commercial success in China.
Key Webinar Topics
- Latest trends on the pricing and market access landscape in China
- What access pathways/programs are available for innovative products
- Insights from recent launches
Featuring
Wenting Zhang
Director,
Evidence, Value, Access & Pricing
Allen Liu
Senior Consultant & APAC Expert,
Strategic Advisory
Yitong Li
Senior Consultant & APAC Expert,
Strategic Advisory
In Part 3 of this webinar series, our experts will explore:
Part 3: The Winning Commercial Model | Upcoming
Building a model to match China’s changing dynamics
Complete the form below to view the on-demand webinar
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Briefs
Unlocking Environmental Sustainability Opportunities in the Life Sciences
The healthcare industry has long been known for its significant environmental impact, including contributing ~5% of total global emissions. As awareness of this impact has increased, life sciences companies are now actively committing to climate resilience and environmental sustainability through various initiatives, including net-zero commitments. Trinity Life Sciences has identified several recent trends driving this […]
Read More
Briefs
Global Dossiers in the Joint Clinical Assessment Era: Impacts and Implications
Joint clinical assessment (JCA) is a European Union (EU) initiative intended to improve patient access to health technologies in Europe through a harmonized clinical health technology assessment (HTA) process. From January 2025, all new oncology medicines and advanced therapy medicinal products will go through the JCA process, followed by all orphan medicinal products from 2028 […]
Read More
Briefs
Assessing the Influence of ICER Reports on U.S. Payer Decision Making
The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research organization dedicated to assessing the value of healthcare interventions, including diagnostics, devices, digital therapeutics and prescription drugs. Although ICER’s assessments do not represent a mandate for product funding or pricing in the U.S. in the same way as, for example, National Institute […]
Read More